A Phase 1, First-in-Human, Open Label, Dose Escalation, Dose Optimization, and Cohort Expansion Study of MGC030 in Participants With Advanced Solid Tumors
Considering participating in a START clinical trial?
Study Summary
The study is designed to characterize safety, tolerability, pharmacokinetics, immunogenicity, and preliminary anti-tumor activity of MGC030 in participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tumors of select types. It also aims to assess whether MGC030 can cause tumor shrinkage, disease stabilization, or control disease progression.
The main question the study aims to answer is:
What types of side effects will participants experience when receiving MGC030?Can MGC030 cause cancer to shrink, remain stable, or able to control disease progression of participants with advanced solid tumors? Participants willUndergo screening procedures to determine eligibilityReceive study treatments initially every 3 weeks.Have blood samples taken for routine and research testsHave other examinations to check heart and lung function, and general health statusBe asked about any side effects that may be happening or other medications you are taking. The study doctor will provide treatment for side effects, if necessary.Have the study doctor assess your tumor status at regular intervals to determine how you are responding to treatment.
- Participants in dose escalation cohorts must have histologically proven unresectable, locally advanced or metastatic solid tumor limited to one of the following types: urothelial cancer, colorectal cancer (CRC), gastric or gastroesophageal junction (GEJ) cancer, esophageal cancer, or pancreatic carcinoma that is refractory to standard therapy, or for which standard therapy does not exist, has proven to be intolerable, or has been refused by the participant.
- * Participants in expansion cohorts must have histologically proven, unresectable, locally advanced or metastatic solid tumors
- * Urothelial cancer with progression following platinum-containing chemotherapy for metastatic or locally advanced/unresectable cancer, or within 12 months from completion of neo-adjuvant or adjuvant platinum-containing chemotherapy for localized muscle-invasive cancer.
- * Gastric/GEJ carcinoma with progression during or following at least 1 systemic therapy.
- * Esophageal cancer with progression during or following at least 1 systemic therapy.
- * CRC with progression during or following treatment with at least 2 prior lines of systemic therapy (containing a fluoropyrimidine plus a platinum analogue and/or irinotecan) for metastatic disease.
- * CRC harboring an activating EGFR mutation must have progressed during or following at least one EGFR targeted therapy, if available.
- * Participants should have received no more than 4 prior lines of systemic therapy for advanced or metastatic disease.
- * Pancreatic cancer with progression during or following at least 1 systemic therapy. Participants should have received no more than 2 prior lines of cytotoxic chemotherapy for advanced or metastatic disease.
- * Participants must have at least one lesion that meets the definition of measurable disease by RECIST v1.1.
- * Participants must have an available archival or formalin-fixed paraffin-embedded tumor tissue or be willing to undergo a biopsy procedure to obtain a fresh tumor sample.
- * Participants have acceptable physical condition and laboratory values.
- * Participants of childbearing potential must agree to use highly effective methods of birth control.
- * Participants must not be pregnant, planning to be pregnant, or breastfeeding.
- Any underlying medical or psychiatric condition impairing participant's ability to receive, tolerate, or comply with the planned treatment or study procedures.
- * Active brain metastases or leptomeningeal metastases.
- * Prior stem cell, tissue, or solid organ transplant.
- * Another malignancy that required treatment within the past 2 years, with the exception of those with a negligible risk of metastasis or death such as adequately treated non-melanomatous skin cancer, localized prostate cancer (Gleason Score < 6), or carcinoma in situ.
- * History of primary immunodeficiency.
- * Active viral, bacterial, or fungal infection
- * Prior treatment with Topoisomerase 1-based ADCs for cancer.
- * Prior treatment with major surgery, mediastinal or lung radiation, vaccination with live virus vaccines, systemic cancer treatment, chimeric antigen receptor (CAR)-T cell therapy, or experimental treatment within 4 weeks of the start of study treatment.
Clinical Study Information for Healthcare Providers
By clicking the button below you will find in-depth information about this clinical trial, including study design, primary and secondary endpoints, and more. This information is intended for healthcare professionals seeking to review the scientific and operational aspects of the study.